Abstract
This study investigated the therapeutic effects of interleukin (IL)-2 and granulocyte-macrophage colony-stimulating factor (GM-CSF) co-administrated with antibacterial agents isoniazid (INH) and rifampin (RIF) to treat a mouse model of tuberculosis (TB) infection. A drug-susceptible TB strain, H37Rv was used to infect mice and the effectiveness of IL-2 and GM-CSF was initially evaluated based on survival rate, bacterial counts in lungs and spleens and the pathological condition of the lungs. Next, the therapeutic effect of the immunotherapy regimen was assessed in multidrug-resistant strain OB35-infected mice. In the H37Rv infection model, IL-2 and GM-CSF monotherapies reduced bacterial numbers in the lungs by 0.82 (P<0.01) and 0.58 (P<0.05) lg colony-forming units (CFU), respectively, and in the spleens by 1.42 (P<0.01) and 1.22 (P<0.01) lg CFU, respectively, compared with the untreated group. Mice receiving immunotherapy developed fewer lesions in the lungs compared with mice receiving antibacterial therapy alone. In the OB35 infection model, immunotherapy with either cytokine resulted in a significant reduction of bacterial load in the lungs and spleens and less severe lesions in the lungs compared with the untreated or antibacterial therapy treated mice. Notably, mice receiving immunotherapy with both cytokines had a 30% survival rate which was higher than that in other treated groups, and had significantly less CFUs in the lungs and spleens (1.02 and 1.34 lg CFU) compared with antibacterial therapy alone (P<0.01). This study demonstrated that immunotherapy with both IL-2 and GM-CSF may be useful to treat multidrug resistant tuberculosis (MDR-TB).
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
World Health Organization. Global Tuberculosis Control: Epidemiology, Strategy, Financing. WHO, 2009
World Health Organization. Global Tuberculosis Control 2010. WHO, 2010
Nuermberger E L, Spigelman M K, Yew W W. Current development and future prospects in chemotherapy of tuberculosis. Respirology, 2010, 15: 764–778
Masihi K N. Fighting infection using immunomodulatory agents. Expert Opin Biol Ther, 2001, 1: 641–653
Urdahl K B, Shafiani S, Ernst J D. Initiation and regulation of T-cell responses in tuberculosis. Mucosal Immunol, 2011, 4: 288–293
Cooper A M, Mayer-Barber K D, Sher A. Role of innate cytokines in mycobacterial infection. Mucosal Immunol, 2011, 4: 252–260
Abebe F, Bjune G. The protective role of antibody responses during Mycobacterium tuberculosis infection. Clin Exp Immunol, 2009, 157: 235–243
Coleman D L, Chodakewitz J A, Bartiss A H, et al. Granulocyte-macrophage colony-stimulating factor enhances selective effector functions of tissue-derived macrophages. Blood, 1988, 72: 573–578
Suzuki K, Lee W J, Hashimoto T, et al. Recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) or tumour necrosis factor-alpha (TNF-alpha) activate human alveolar macrophages to inhibit growth of Mycobacterium avium complex. Clin Exp Immunol, 1994, 98: 169–173
Berretta F, St-Pierre J, Piccirillo C A, et al. IL-2 contributes to maintaining a balance between CD4+ Foxp3+ regulatory T cells and effector CD4+ T cells required for immune control of blood-stage malaria infection. J Immunol, 2011, 186: 4862–4871
Yamamura M, Uyemura K, Deans R J, et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science, 1991, 254: 277–279
Wnr R C, Liu Y M, Schluger N W. Local immune responses correlated with presentation and outcome in tuberculosis. Am J Respir Crit Care Med, 1998, 157: 729–735
Tan Q, Xie W P, Min R, et al. Characterization of Th1- and Th2-type immune response in human multidrug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis, 2012, 31: 1233–1242
Cai H, Yu D H, Tian X, et al. Coadministration of interleukin 2 plasmid DNA with combined DNA vaccines significantly enhances the protective efficacy against Mycobacterium tuberculosis. DNA Cell Biol, 2005, 24: 605–613
Nambiar J K, Ryan A A, Kong C U, et al. Modulation of pulmonary DC function by vaccine-encoded GM-CSF enhances protective immunity against Mycobacterium tuberculosis infection. Eur J Immunol, 2010, 40: 153–161
Zhuang Y, Li G, Zhang X, et al. Study of recombinant IL-2 on Mycobacterium tuberculosis infected mice. Xian Dai Mian Yi Xue, 1992, 12: 3
Chun N H, Zhu L Z, Yie Z Z, et al. A controlled clinical study on the efficacy of recombinant human interleukin-2 in the treatment of pulmonary tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi, 2003, 26: 548–551
Bermudez L E, Martinelli J, Petrofsky M, et al. Recombinant granulocyte-macrophage colony-stimulating factor enhances the effects of antibiotics against Mycobacterium avium complex infection in the beige mouse model. J Infect Dis, 1994, 169: 575–580
Pedral-Sampaio D B, Netto E M, Brites C, et al. Use of Rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial. Braz J Infect Dis, 2003, 7: 245–252
Lu J, Yue J, Wu J, et al. In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis. Pharmacology, 2010, 85: 365–371
Watson V E, Hill L L, Owen-Schaub L B, et al. Apoptosis in Mycobacterium tuberculosis infection in mice exhibiting varied immunopathology. J Pathol, 2000, 190: 211–220
Liang Y, Wu X, Zhang J, et al. Treatment of multi-drug-resistant tuberculosis in mice with DNA vaccines alone or in combination with chemotherapeutic drugs. Scand J Immunol, 2011, 74: 42–46
Liang Y, Wu X, Zhang J, et al. The treatment of mice infected with multi-drug-resistant Mycobacterium tuberculosis using DNA vaccines or in combination with rifampin. Vaccine, 2008, 26: 4536–4540
Aslanzadeh J, de la Viuda M, Fille M, et al. Comparison of culture and acid-fast bacilli stain to PCR for detection of Mycobacterium tuberculosis in clinical samples. Mol Cell Probes, 1998, 12: 207–211
Gebre N, Karlsson U, Jonsson G, et al. Improved microscopical diagnosis of pulmonary tuberculosis in developing countries. Trans R Soc Trop Med Hyg, 1995, 89: 191–193
Arnaud L, Gorochov G, Charlotte F, et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood, 2011, 117: 2783–2790
Katsikis P D, Mueller Y M, Villinger F. The cytokine network of acute HIV Infection: a promising target for vaccines and therapy to reduce viral set-point? PLoS Pathog, 2011, 7: e1002055
Szeliga J, Daniel D S, Yang C H, et al. Granulocyte-macrophage colony stimulating factor-mediated innate responses in tuberculosis. Tuberculosis (Edinb), 2008, 88: 7–20
Toubaji A, Hill S, Terabe M, et al. The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long-term tumor protection. Vaccine, 2007, 25: 5882–5891
Ahlers J D, Dunlop N, Alling D W, et al. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J Immunol, 1997, 158: 3947–3958
Author information
Authors and Affiliations
Corresponding authors
Additional information
This article is published with open access at Springerlink.com
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Zhang, Y., Liu, J., Wang, Y. et al. Immunotherapy using IL-2 and GM-CSF is a potential treatment for multidrug-resistant Mycobacterium tuberculosis. Sci. China Life Sci. 55, 800–806 (2012). https://doi.org/10.1007/s11427-012-4368-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-012-4368-x